Navidea biopharmaceuticals announces first 110 subjects imaged in nav3-35 normative database phase 2b study to support rheumatoid arthritis indications

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that over 110 subjects have been enrolled and imaged in its nav3-35 phase 2b study, “development of a normative database for rheumatoid arthritis (ra) imaging with tc99m tilmanocept.” expected total enrollment for this two-arm trial will be 135 participants. nav3-35 wi
NAVB Ratings Summary
NAVB Quant Ranking